Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer

INTRODUCTION: Therapeutically induced androgen deficiency (AD) is a standard treatment for patients with prostate cancer, but it is often associated with various adverse effects (AEs) that may lead to discontinuation. Some AEs may depend on the patient’s health condition, while others may be due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokiwa, Suguru, Shimmura, Hiroaki, Nomura, Shuhei, Watanabe, Ryota, Kurita, Minoru, Yoshida, Naoto, Yamashita, Kaori, Nishikawa, Yoshitaka, Kouzmenko, Alexander, Kato, Shigeaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724412/
https://www.ncbi.nlm.nih.gov/pubmed/29264358
http://dx.doi.org/10.2147/RRU.S146180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724412/
https://www.ncbi.nlm.nih.gov/pubmed/29264358
http://dx.doi.org/10.2147/RRU.S146180

Ejemplares similares